恩瑞格对铁质积聚有多大的疗效呢？

It is used to treat chronic iron overload in beta-thalassemia patients older than 6 years old due to frequent blood transfusions (monthly administration of concentrated red blood cells ≥7mL/kg); for children under 6 years old and iron overload caused by other transfusion-dependent diseases, how effective is Enrig in treating iron accumulation?

Therapeutic effects of Enrige in treating iron accumulation:

Objective: To compare the effects of Enrig and deferoxamine in the treatment of transfusion-dependent thalassemia (TDT), and evaluate the advantages and limitations of monotherapy.

The case data of TDT combined with iron overload and treated with Enreg or deferoxamine from January 2013 to June 2015 were retrospectively analyzed.

Fifty-eight children in the Enrig group were treated with Enrig 20~35 mg/(kg·d), and 27 children in the deferoxamine group were treated with deferoxamine 25~45 mg/(kg·d), 5 days a week. The patients were followed up for 1 year since taking the drug, and serum ferritin (SF) level, liver and kidney function, and blood routine were measured every 3 to 6 months.

Results: There was no statistically significant difference in the median age, average iron intake rate and pre-treatment SF between the two groups of children.

After 6 months of follow-up, the mean SF decreases in the Enriga group and the Deferoxamine group were 168 (-2 650, 7 254) ng/mL and 170 (-260, 599) ng/mL respectively (P>0.05).

The decrease in SF in the Enrig group was positively correlated with dose (P<0.05). After 7 to 12 months of follow-up, the mean SF reduction values ​​in the Enriga group and the deferoxamine group were 212 (-370, 795) ng/mL and -1 330 (-2 454, -206) ng/mL respectively (P<0.05).

Conclusion: Enriga has advantages over deferoxamine in the treatment of TDT, and the maximum dose within the tolerance range should be used. Enriga can stabilize SF and should be used for a long time.

There is no unified answer to the question of how many courses of treatment should be used, because each patient's condition and physical condition are different. Some patients have better physical constitution and milder conditions. Enrig's treatment is easier to work in the patient's body and heals faster. Generally, one or two courses of treatment is enough, while patients with poor physical fitness or severe illness need to use it for a longer period of time to be effective.